Pfizer Gets CDSCO Panel Nod to Study Sisunatovir in Adults With Respiratory Syncytial Virus Infection

RSV infects the target cell via the attachment of G protein, followed by fusion of the virus and host cell membrane mediated by F protein, resulting in release of the genomic RNA into the cytoplasm.

Sisunatovir is an orally available, small molecule inhibitor of human respiratory syncytial virus (RSV) fusion protein (F protein), with potential antiviral activity. Upon oral administration, sisunatovir specifically targets and binds to RSV-F protein on the viral surface, which inhibits RSV-F protein-mediated fusion with the host cell membrane and prevents viral entry. This blocks RSV replication, reduces viral load, and decreases the severity of the disease. RSV-F protein, a viral surface glycoprotein, plays a key role in RSV fusion with and entry into target cells.

At the recent SEC meeting for antimicrobial and antiviral held on 21st February 2023, the expert panel reviewed the Phase 2/3 clinical trial protocol No. C5241007 presented by drug major Pfizer.

After detailed deliberation, the committee recommended the grant of permission to conduct the clinical trial as presented by the firm.

Also Read: Dr Mansukh Mandaviya inaugurates CDSCO Sub Zonal Office, Central Drug Testing Laboratory in Indore